Navigation Links
Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
Date:9/7/2012

Astex Pharmaceuticals, Inc (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

The collaboration combines Astex's world-renowned fragment-based drug discovery platform and epigenetic* drug development experience with the expertise in blood cancer biology at The Institute of Cancer Research (ICR) and proven success in drug discovery at the Cancer Research UK Cancer Therapeutics Unit at the ICR.

Dysregulated epigenetic mechanisms are now understood to underlie a variety of cancer types, and have been successfully targeted by the first generation of epigenetic anticancer drugs**. In some cases, specific epigenetic mutational events can be linked to disease etiology, providing an opportunity to develop highly targeted personalised medicines and associated companion diagnostics that will ultimately improve survival and reduce side effects.

"We are delighted to be entering into this new collaboration with the ICR and CRT on a key epigenetics target," said Harren Jhoti, PhD, president of Astex Pharmaceuticals. "This new partnership builds on the highly successful collaboration which Astex entered into with the ICR and CRT in 2003 on another cancer target, PKB/Akt. That collaboration led to the discovery of two clinical candidates, the first of which, AZD5363, was taken into Phase I by our partner AstraZeneca in early 2011 and the second of which, AT13148, is being prepared to be taken into Phase 1 under our development partnership with Cancer Research UK. "

Professor Paul Workman, director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, said: "ICR scientists are pioneers at unravelling blood cancer drug targets, which others have considered challenging to drug effectively. We have a very strong track record of designing drugs to attack challenging biological targets and bringing them into clinical trial, and given Astex's complementary expertise, we are very excited about the potential of this collaboration."

Dr Phil L'Huillier, director of business management at CRT, said: "Putting in place this collaboration between the Cancer Research UK-funded drug discovery team at the ICR and Astex provides a powerful route to identify drug candidates for this promising new target.

"The deal will ensure that the research programme benefits from the necessary investment to progress the research to its full potential while building on the validation and assay development work that has been carried out at the ICR and funded by Cancer Research UK and others.

"We hope that this research will lead to the development of new drugs to ultimately improve survival for cancer patients."


'/>"/>
Contact: Jane Bunce
jane.bunce@icr.ac.uk
44-207-153-5106
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
2. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
3. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
4. A North American first at the Montreal Heart Institute
5. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
6. Data release from the Allen Institute for Brain Science expands online atlas offerings
7. Los Robles Hospital’s Annual Health Fair Attended by Khanna Institute
8. Patient Experience Regional Roundtables Announced by The Beryl Institute
9. Stanford Woods Institute for the Environment announces 2012 Environmental Venture Project awards
10. Aetna Institute Designates RSC New England Center of Excellence
11. To tackle health cares thorniest problems, 400 health researchers form new U-M-based institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 2017 , ... Ray Insurance Agencies, a Dallas area firm providing asset protection ... on a six month charity event aimed at raising local support and donations that ... of the deadliest diseases in America; more than 7.5 million people die from cancer ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... further expansion of its eHealth App xChange™, providing clinical researchers more choices ... extensive and growing eHealth platform. Applications that enable patient-centered clinical trials make ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is the largest ... demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and Epic. , ... no Health Information Exchange outside of faxing. Medal’s innovative technology “meets providers where ...
(Date:2/21/2017)... Boca Raton, FL (PRWEB) , ... February 21, ... ... development of unique, coffee house-caliber protein espresso drinks, announced its products are now ... , CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers ...
(Date:2/20/2017)... ... February 20, 2017 , ... MRI screening improves early diagnosis of breast ... Germany published online in the journal Radiology . , MRI has long ... mammography and ultrasound. Currently, guidelines reserve breast MRI screening for women who have a ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 2017 Micro Guide Catheters Market: Overview ... Micro Guide Catheters are used ... clinics and ambulatory surgery centers etc. Micro guide ... selection of micro guide catheter depends on the ... body. Micro guide catheters are available in different ...
(Date:2/21/2017)... 2017  Luminex Corporation (NASDAQ: LMNX ) (the ... the initiation of a quarterly cash dividend to its shareholders, ... will be payable on April 14, 2017 to shareholders of ... 2017. The board of directors intends for ... $0.06 to holders of its common stock, representing a planned ...
(Date:2/21/2017)... CLEVELAND , Feb. 21, 2017  /PR Newswire/ ... is pleased to announce the launch of Modern ... educational website for retina specialists. Built upon ... Retina focuses on the latest innovations in the ... technology, and practice management. By meeting current informational needs ...
Breaking Medicine Technology: